These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18805722)

  • 1. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.
    Ramsubir S; Nonaka T; Girbés CB; Carpentier S; Levade T; Medin JA
    Mol Genet Metab; 2008 Nov; 95(3):133-41. PubMed ID: 18805722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates.
    Walia JS; Neschadim A; Lopez-Perez O; Alayoubi A; Fan X; Carpentier S; Madden M; Lee CJ; Cheung F; Jaffray DA; Levade T; McCart JA; Medin JA
    Hum Gene Ther; 2011 Jun; 22(6):679-87. PubMed ID: 21280983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell transplantation leads to biochemical and functional correction in two mouse models of acid ceramidase deficiency.
    Rybova J; Sundararajan T; Kuchar L; Dlugi TA; Ruzicka P; McKillop WM; Medin JA
    Mol Ther; 2024 Oct; 32(10):3402-3421. PubMed ID: 39108096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.
    Gao Z; Golob J; Tanavde VM; Civin CI; Hawley RG; Cheng L
    Stem Cells; 2001; 19(3):247-59. PubMed ID: 11359950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic ceramide accumulation leads to severe and varied pathological consequences.
    Alayoubi AM; Wang JC; Au BC; Carpentier S; Garcia V; Dworski S; El-Ghamrasni S; Kirouac KN; Exertier MJ; Xiong ZJ; Privé GG; Simonaro CM; Casas J; Fabrias G; Schuchman EH; Turner PV; Hakem R; Levade T; Medin JA
    EMBO Mol Med; 2013 Jun; 5(6):827-42. PubMed ID: 23681708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of a tCD25 preselective combination anti-HIV lentiviral vector in human hematopoietic stem and progenitor cells.
    Barclay SL; Yang Y; Zhang S; Fong R; Barraza A; Nolta JA; Torbett BE; Abedi M; Bauer G; Anderson JS
    Stem Cells; 2015 Mar; 33(3):870-9. PubMed ID: 25524029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
    Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
    Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    Beckmann N; Becker KA; Kadow S; Schumacher F; Kramer M; Kühn C; Schulz-Schaeffer WJ; Edwards MJ; Kleuser B; Gulbins E; Carpinteiro A
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells.
    Imren S; Fabry ME; Westerman KA; Pawliuk R; Tang P; Rosten PM; Nagel RL; Leboulch P; Eaves CJ; Humphries RK
    J Clin Invest; 2004 Oct; 114(7):953-62. PubMed ID: 15467834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy.
    Schuchman EH
    Biochim Biophys Acta; 2016 Sep; 1862(9):1459-71. PubMed ID: 27155573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell targeting with surface-engineered lentiviral vectors.
    Verhoeyen E; Cosset FL
    Cold Spring Harb Protoc; 2009 Aug; 2009(8):pdb.prot5276. PubMed ID: 20147252
    [No Abstract]   [Full Text] [Related]  

  • 12. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
    Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
    Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein.
    Di Nunzio F; Piovani B; Cosset FL; Mavilio F; Stornaiuolo A
    Hum Gene Ther; 2007 Sep; 18(9):811-20. PubMed ID: 17824830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentiviral vector integration sites in human NOD/SCID repopulating cells.
    Laufs S; Guenechea G; Gonzalez-Murillo A; Zsuzsanna Nagy K; Luz Lozano M; del Val C; Jonnakuty S; Hotz-Wagenblatt A; Jens Zeller W; Bueren JA; Fruehauf S
    J Gene Med; 2006 Oct; 8(10):1197-207. PubMed ID: 16960916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease.
    Hofling AA; Devine S; Vogler C; Sands MS
    Mol Ther; 2004 Jun; 9(6):856-65. PubMed ID: 15194052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.
    Li YJ; Chen C; Zeng LY; Cao J; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells.
    Medin JA; Takenaka T; Carpentier S; Garcia V; Basile JP; Segui B; Andrieu-Abadie N; Auge N; Salvayre R; Levade T
    Hum Gene Ther; 1999 May; 10(8):1321-9. PubMed ID: 10365663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplantation in Farber disease.
    Ehlert K; Levade T; Di Rocco M; Lanino E; Albert MH; Führer M; Jarisch A; Güngör T; Ayuk F; Vormoor J
    J Inherit Metab Dis; 2019 Mar; 42(2):286-294. PubMed ID: 30815900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    Dworski S; Lu P; Khan A; Maranda B; Mitchell JJ; Parini R; Di Rocco M; Hugle B; Yoshimitsu M; Magnusson B; Makay B; Arslan N; Guelbert N; Ehlert K; Jarisch A; Gardner-Medwin J; Dagher R; Terreri MT; Lorenco CM; Barillas-Arias L; Tanpaiboon P; Solyom A; Norris JS; He X; Schuchman EH; Levade T; Medin JA
    Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):386-394. PubMed ID: 27915031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy.
    Elsea SH; Solyom A; Martin K; Harmatz P; Mitchell J; Lampe C; Grant C; Selim L; Mungan NO; Guelbert N; Magnusson B; Sundberg E; Puri R; Kapoor S; Arslan N; DiRocco M; Zaki M; Ozen S; Mahmoud IG; Ehlert K; Hahn A; Gokcay G; Torcoletti M; Ferreira CR
    Hum Mutat; 2020 Sep; 41(9):1469-1487. PubMed ID: 32449975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.